NewsRoom Articles - Page 121 of 207

FridayJan 07, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Signs LOI with Maya to Co-Develop a Prescription Digital Therapeutics Platform Targeting a Trifecta Approach to Patient Care

Mydecine has signed a letter of intent with Maya detailing a collaborative partnership to develop a novel digital therapeutics (“DTx”) platform The DTx platform is expected to create a three-pronged approach to patient care by combining Mydecine’s Mindleap digital health platform with its medication-based treatments According to COO Damon Michaels, the new platform will provide improved adherence to treatment protocols, patient experience, biometric insights, and post-approval insurance reimbursements Both companies intend to pursue rigorous studies to achieve FDA clearance Regarded as the convergence of health care and software that has resulted in a new crop of life sciences technology helping…

ThursdayJan 06, 2022 2:29 pm

Timely Initiation of Treatment Improves Opioid Use Disorder Outcomes

Researchers at the University of Pennsylvania’s School of Medicine have discovered that a program which was designed to make buprenorphine administration timely and easy has increased the use of the treatment in hospital emergency departments significantly. Buprenorphine is a drug that’s used to stabilize opioid withdrawal and pacify cravings. The medication’s use can decrease overdose deaths and other complications associated with drug use while growing long-term engagement with care for opioid use disorder. The lead author of the study, Margaret Lowenstein, stated that the researchers utilized a behavioral design approach to make the execution of evidence-based treatment timely, attractive and…

ThursdayJan 06, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key Meeting with UK Regulatory Agency

Meeting takes company a step closer to advancing its lead investigational candidate CYB003 into clinical development CYB003 is designed for the treatment of two significant conditions: major depressive disorder (“MDD”) and alcohol use disorder (“AUD”) CEO notes that CYB003 has the potential to achieve better patient outcomes The coming year holds significant promise for Cybin (NEO: CYBN) (NYSE American: CYBN) for numerous reasons. The biopharmaceutical company has seen significant success in the execution of its strategic focus on progressing psychedelics to therapeutics, including its recent announcement that company representatives will hold a scientific advice meeting with the UK Medical and Healthcare…

WednesdayJan 05, 2022 11:53 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Entering 2022 With Multiple Clinical Trials Including MYCO-001 for Smoking Cessation

Mydecine has partnered with Dr. Matthew Johnson and Johns Hopkins University for two upcoming trials for MYCO-001 – a psilocybin approach to smoking cessation The company is positioned to fill a billion-dollar hole in the industry after the leading pharmaceutical Chantix was removed from the market due to cancer risks Two previous psilocybin trials conducted by Dr. Johnson, show promising results for the use of psilocybin as a smoking cessation tool when paired with cognitive behavioral therapy (“CBT”) Smoking remains among the leading public health concerns of the 21st century. The total number of tobacco-related deaths worldwide has reached six…

WednesdayJan 05, 2022 9:30 am

New Study Explores Whether mRNA Vaccines Could Help Against Cancer

The German pharmaceutical firm that worked with Pfizer in 2020 to develop the first coronavirus vaccine is now developing a new vaccine that harnesses the same mRNA technology it used to create an mRNA cancer vaccine. The firm, BioNTech, is currently conducting a phase 2 clinical trial for the experimental vaccine, which involves participants with cancer. BioNTech was founded more than a decade ago, with its CEO, Dr. Uğur Şahin, revealing that the company’s objective is to develop cancer therapies. The company isn’t the only one focused on developing mRNA vaccines for various indications, as the technology is said to…

TuesdayJan 04, 2022 10:42 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Milestone Notice of Allowance for Revolutionary Treatment of Anxiety Disorders

USPTO notice marks important milestone in the expansion of CYBN’s intellectual property portfolio Once issued, patent may have opportunity to cover a broad range of claims Anxiety disorders are one of the most common mental illnesses in the United States Cybin (NEO: CYBN) (NYSE American: CYBN) has taken another step forward in its commitment to progressing Psychedelics to Therapeutics(TM). The biopharmaceutical company has received a notice of allowance from the U.S. Patent and Trademark Office (“USPTO”) in regard to its patent application connected to its investigational deuterated psychedelic tryptamine compound for the potential treatment of anxiety disorders (https://ibn.fm/fpjXm). “The receipt of…

TuesdayJan 04, 2022 9:30 am

Common Applications of Predictive Analytics in the Healthcare Industry

Predictive analytics are a form of technology that make forecasts about specific unknowns in the future. The technology’s use in healthcare offers various benefits, primarily in operational management, administrative tasks and clinical care. The tech is already delivering value in different healthcare settings, including large academic hospitals, healthcare insurance firms and small private physician practices. The technology’s numerous benefits include reductions in cost of healthcare, more consistent patient care and improved patient outcomes. It is expected that the use of predictive analytics in the healthcare industry will become more widespread in the near future. Today, we look at some of…

MondayJan 03, 2022 9:30 am

AI May Soon Replace Mice Models in Brain Cancer Research

Studying tumor growth and treatment is a crucial part of cancer research because it aids in the development of more effective treatments. Despite decades of research, however, drug identification for the treatment of brain cancer is still slow. This is mainly due to the lack of better models for research. This may soon change after Uppsala University researchers used artificial intelligence (“AI”) to develop a new technique to study brain cancer. The technique is based on the transplantation of tumor cells to zebrafish embryos, which are then observed using AI. This technique can partially replace the mouse models that are…

ThursdayDec 30, 2021 9:30 am

Study Finds That Prolonged Sitting Increases Anxiety, Depression

The coronavirus pandemic and the subsequent lockdowns and restrictions imposed as a result to help contain virus spread have impeded a lot of movement. Social distancing has limited social gatherings and people have been allowed to work from home, which has led to increased sedentary behaviors. This sedentary way of life, while reducing work-home commutes and allowing us to stay home more, could be problematic. New research has found that a lack of movement not only impacts our physical health but our mental health as well. The study found that remaining seated for a considerable amount of time was linked…

ThursdayDec 30, 2021 9:00 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Inches Closer to iSTRYM’s Commercial Deployment; Announces Dr. Doron Sagman’s Appointment as CMO; and Avails Recent Life Sciences Virtual Conference Presentation for On-Demand Viewing

MINDCURE just announced receiving its HIPAA certification for iSTRYM, its AI-powered, SaaS platform for psychedelic therapy This marks a key milestone for the company, having already exceeded its target of 10 partner clinics by the end of 2021 It also inches the company closer to the platform’s commercial deployment, set for the second quarter of 2022 This comes just in time, following the appointment of Dr. Doron Sagman as the company’s new CMO MINDCURE’s Life Sciences Virtual Conference Presentation will also be available for on-demand viewing 24/7 for the next 90 days Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) has…